The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease

• Published in: Scientific reports 2017-12, Vol.7 (1), p.17193-13, Article 17193
• Main Authors: Cazanave, Sophie, Podtelezhnikov, Alexei, Jensen, Kristian, Seneshaw, Mulugeta, Kumar, Divya P., Min, Hae-Ki, Santhekadur, Prasanna K., Banini, Bubu, Mauro, Adolfo Gabriele, M. Oseini, Abdul, Vincent, Robert, Tanis, Keith Q., Webber, Andrea L., Wang, Liangsu, Bedossa, Pierre, Mirshahi, Faridoddin, Sanyal, Arun J.
• Format: Article
• Language: English
• Subjects: 38; 38/39; 38/61; 692/420; 692/699/317; Animals; Apoptosis; Cancer; Cell activation; Cell death; Cellular stress response; Diapedesis; Disease Progression; Fatty liver; Fibrosis; Gene expression; Gene Expression Profiling; Humanities and Social Sciences; Interleukin 1; Leukocytes (granulocytic); Lipid peroxidation; Lipogenesis; Liver; Liver Cirrhosis - complications; Liver diseases; Macrophages; Male; Metabolic rate; Metabolism; Mice; Mice, Inbred C57BL; multidisciplinary; Non-alcoholic Fatty Liver Disease - complications; Non-alcoholic Fatty Liver Disease - genetics; Non-alcoholic Fatty Liver Disease - pathology; Oxidative stress; Peroxisome proliferator-activated receptors; Prothrombin; Retinoid X receptors; Rodents; Science; Science (multidisciplinary); Signal Transduction; Sugar; Transcription activation
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-017-17370-6

A longitudinal molecular model of the development and progression of nonalcoholic fatty liver disease (NAFLD) over time is lacking. We have recently validated a high fat/sugar water-induced animal (an isogenic strain of C57BL/6 J:129S1/SvImJ mice) model of NAFLD that closely mimics most aspects of human disease. The hepatic transcriptome of such mice with fatty liver (8 weeks), steatohepatitis with early fibrosis (16–24 weeks) and advanced fibrosis (52 weeks) after initiation of the diet was evaluated and compared to mice on chow diet. Fatty liver development was associated with transcriptional activation of lipogenesis, FXR-RXR, PPAR-α mediated lipid oxidation and oxidative stress pathways. With progression to steatohepatitis, metabolic pathway activation persisted with additional activation of IL-1/inhibition of RXR, granulocyte diapedesis/adhesion, Fc macrophage activation, prothrombin activation and hepatic stellate cell activation. Progression to advanced fibrosis was associated with dampening of metabolic, oxidative stress and cell stress related pathway activation but with further Fc macrophage activation, cell death and turnover and activation of cancer-related networks. The molecular progression of NAFLD involves a metabolic perturbation which triggers subsequent cell stress and inflammation driving cell death and turnover. Over time, inflammation and fibrogenic pathways become dominant while in advanced disease an inflammatory-oncogenic profile dominates.